Rubius Therapeutics RUBY

$ 0.08 -33.55%

Annual report 2022
added 02-27-2023

Rubius Therapeutics Balance Sheet 2011-2024 | RUBY

Annual Balance Sheet Rubius Therapeutics

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-141 M	-14.1 M	149 M	-186 M	-98.8 M	-2.91 M	-	-	-	-	-
Long Term Debt	-	76.2 M	32.8 M	49.6 M	24.3 M	3.3 M	2.99 M	-	-	-	-	-
Long Term Debt Current	1.1 M	9.02 M	8.94 M	10.5 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	86.9 M	66.1 M	144 M	22.3 M	-	-	-	-	-
Total Current Liabilities	7.94 M	34.7 M	27.8 M	33.8 M	20 M	-	-	-	-	-	-	-
Total Liabilities	7.94 M	139 M	136 M	121 M	86.1 M	151 M	25.1 M	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-857 M	-677 M	-480 M	-313 M	-150 M	-61 M	-17.1 M	-	-	-	-	-
Total Assets	23.1 M	318 M	278 M	395 M	479 M	108 M	7.99 M	-	-	-	-	-
Cash and Cash Equivalents	14.9 M	226 M	92.9 M	91.9 M	307 M	105 M	7.07 M	-	-	-	-	-
Book Value	15.1 M	179 M	142 M	274 M	393 M	-43.7 M	-17.1 M	-	-	-	-	-
Total Shareholders Equity	15.1 M	179 M	142 M	274 M	393 M	-43.7 M	-17.1 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Rubius Therapeutics

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	76.8 M	76.6 M	76.4 M	76.2 M	75.9 M	75.7 M	66.3 M	74.9 M	74.9 M	74.9 M	74.9 M	49.6 M	49.6 M	49.6 M	49.6 M	24.3 M	24.3 M	24.3 M	24.3 M	3.3 M	3.3 M	3.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	134 M	134 M	132 M	139 M	137 M	132 M	129 M	136 M	136 M	136 M	136 M	121 M	121 M	121 M	121 M	86.1 M	86.1 M	86.1 M	86.1 M	11.6 M	11.6 M	11.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-837 M	-774 M	-729 M	-677 M	-622 M	-573 M	-523 M	-480 M	-480 M	-480 M	-480 M	-313 M	-313 M	-313 M	-313 M	-150 M	-150 M	-150 M	-150 M	-61 M	-61 M	-61 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	171 M	229 M	267 M	318 M	361 M	396 M	430 M	278 M	278 M	278 M	278 M	395 M	395 M	395 M	395 M	479 M	479 M	479 M	479 M	108 M	108 M	108 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	104 M	62.2 M	98.1 M	226 M	266 M	285 M	288 M	92.9 M	91.2 M	91.2 M	91.2 M	91.9 M	91.9 M	91.9 M	91.9 M	307 M	307 M	307 M	307 M	104 M	104 M	104 M	-	7.07 M	-	-	-	1.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	36.6 M	95.5 M	135 M	179 M	224 M	264 M	301 M	142 M	142 M	142 M	142 M	274 M	274 M	274 M	274 M	393 M	393 M	393 M	393 M	96.1 M	96.1 M	96.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	36.6 M	95.5 M	135 M	179 M	224 M	264 M	301 M	142 M	142 M	142 M	142 M	274 M	274 M	274 M	274 M	393 M	393 M	393 M	393 M	-43.7 M	-43.7 M	-43.7 M	-	-17.1 M	-	-	-	-5.56 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency